Cargando…
Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report
We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular...
Autores principales: | Sharma, Ashish, Madhusudhan, Rangasamy J, Nadahalli, Vidhya, Damgude, Shreekant A, Sundaramoorthy, Selva K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361827/ https://www.ncbi.nlm.nih.gov/pubmed/22569393 http://dx.doi.org/10.4103/0301-4738.95884 |
Ejemplares similares
-
Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema
por: Altintas, Ayse Gul Kocak, et al.
Publicado: (2019) -
Simultaneous Therapy with Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema
por: de ANDRADE, Felipe L., et al.
Publicado: (2016) -
Intravitreal Bevacizumab for Treatment of Diabetic Macular Edema
por: Seo, Jeong Won, et al.
Publicado: (2009) -
Intravitreal bevacizumab and diabetic papillopathy with macular edema
por: Joob, Beuy, et al.
Publicado: (2012) -
Intravitreal injection of Bevacizumab in diabetic macular edema
por: Ateeq, Asim, et al.
Publicado: (2014)